The Global Patient Reported Outcomes for MS Initiative is looking for an International Program Manager with great organizational, communication, and negotiation skills.
Deadline for MSIF grants and fellowships is 30 June 2020.
Each year, seasoned riders from around the world take on over 400km of the toughest climbs from the Tour De France just weeks before the official race. It's the ride that every cyclist dreams of, but only the toughest can complete.
A new international study has mapped a type of immune cell, the microglia, in the human and mouse brain for the first time. Microglia are thought to play a role in the progression of MS. This research has changed the understanding of how these cells function, and has important implications for MS.
New study shows that early use of high efficacy treatment for MS improves long term disability outcomes, rather than starting on a moderately effective therapy and escalating to a stronger medication.
In a recent study, scientists have shown that people with MS who have food allergies are more likely to experience clinical attacks and lesions in the brain than those without allergies or with other allergies that are unrelated to food.
MSIF’s Atlas of MS with new data on the number of people living with MS across the world, and the challenges they face.
Driving global change - progress made by the global MSIF movement
976 chemicals were screened to assess their impact on MS.